Please login to the form below

Not currently logged in
Email:
Password:

omarigliptin

This page shows the latest omarigliptin news and features for those working in and with pharma, biotech and healthcare.

Merck drops once-weekly diabetes drug in US and EU

Merck drops once-weekly diabetes drug in US and EU

Merck &Co will no longer file for approval of once-weekly diabetes drug omarigliptin in the US or Europe, even though it is already on the market in Japan. ... As recently as last September, Merck was suggesting it would file for approval of omarigliptin

Latest news

More from news
Approximately 2 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...

Infographics